CoChat
Sign Up
Cited by 301Mesenchymal stem cell researchHematopoietic Stem Cell TransplantationPluripotent Stem Cells Research

Comprehensive characterization of four different populations of human mesenchymal stem cells as regards their immune properties, proliferation and differentiation

Open access
LI, XIUYING, BAI, JINPING, JI, XIAOFENG, LI, RONGGUI, XUAN, YALI, WANG, YIMIN·2014·International Journal of Molecular Medicine
DOI 10.3892/ijmm.2014.1821PMC PMC4121354
Open this paper in CoChat — free accountOpen PDF

Abstract

In the present study, we compared mesenchymal stem cells (MSCs) derived from 4 different sources, human bone marrow (BM), adipose tissue (AT), umbilical cord Wharton's Jelly (WJ) and the placenta (PL), in order to determine which population of MSCs displayed the most prominent immunosuppressive effects on phytohemagglutinin-induced T cell proliferation, and which one had the highest proliferative and differentiation potential. MSC and T lymphocyte co-culture (mixed culture) was used to determine whether the MSCs inhibit T cell proliferation, as well as which population of MSCs has the strongest inhibitory ability. The expression of immune-related genes was analyzed by RT-PCR and RT-qPCR. The proliferation and differentiation potential of the MSCs were determined using standard methods. Following MSC and T cell co-culture, mitogen-induced T cell proliferation was effectively suppressed by all 4 populations of MSCs. This occurred through soluble factors rather than direct contact inhibition. Among the 4 populations of MSCs, the WJ-MSC has the strongest suppression effects. On immune related genes, WJ-MSC has the weakest expression of MHC II genes, TLR4, TLR3, JAG1, NOTCH2 and NOTCH3. To compare the proliferation potential, WJ-MSCs showed the most rapid growth rate followed by the AT-, PL- and BM-MSCs. As regards differentiation potential, the WJ-MSCs had the strongest osteogenetic ability followed by PL, AT and BM-MSC. AT-MSC has the strongest adipogenetic ability followed by the WJ-, BM- and PL-MSCs. These data indicated that the WJ-MSCs had the strongest immunomodulatory and immunosuppressive potential. In light of these observations, we suggest that WJ-MSCs are the most attractive cell population for use in immune cellular therapy when immunosuppressive action is required.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3892/ijmm.2014.1821

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Studies comparing the osteogenic potential of human BM-MSCs and ASCs have yielded mixed results.

    “Regarding bone tissue engineering, studies comparing the osteogenic potential of human BM-MSCs and ASCs have yielded mixed results.”

    From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [64]

    The Discussion says AT-MSCs have differentiation potential similar to BM-MSCs, while this study found greater osteogenic potential in AT-MSCs than BM-MSCs. That contrast is consistent with mixed findings, but the earlier statement concerns differentiation generally, not osteogenic potential specifically; the paper does not establish that osteogenic comparisons across studies have yielded mixed results. Page numbers are unavailable in our copy. (LLM, conf=0.78)

    Experimental — accuracy not yet measured

  • Other studies propose that ASCs have equal or superior osteogenic potential compared to BM-MSCs.

    “Some suggest that BM-MSCs exhibit greater osteogenic capacity [58,59,60,61,62], while others propose that ASCs have equal or superior potential [58,63,64,65,66].”

    From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [64]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 51

  1. [1]Friedenstein AJ Chailakhyan RK Latsinik NV Panasyuk AF Keiliss-Borok IV Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo Transplantation 17 331 340 1974 4150881
  2. [2]Caplan AI Mesenchymal stem cells J Orthop Res 9 641 650 1991 1870029
  3. [3]Kopen GC Prockop DJ Phinney DG Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains Proc Natl Acad Sci USA 96 10711 10716 1999 10485891 PMC17948
  4. [4]Pittenger MF Mackay AM Beck SC Multilineage potential of adult human mesenchymal stem cells Science 284 143 147 1999 10102814
  5. [5]Beltrami AP Cesselli D Bergamin N Multipotent cells can be generated in vitro from several adult human organs (heart, liver, and bone marrow) Blood 110 3438 3446 2007 17525288
  6. [6]Fan CG Zhang QJ Zhou JR Therapeutic potentials of mesenchymal stem cells derived from human umbilical cord Stem Cell Rev 7 195 207 2011 20676943
  7. [7]Mosna F Sensebe L Krampera M Human bone marrow and adipose tissue mesenchymal stem cells: a user’s guide Stem Cells Dev 19 1449 1470 2010 20486777
  8. [8]Friedenstein AJ Petrakova KV Kurolesova AI Frolova GP Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues Transplantation 6 230 247 1968 5654088
  9. [9]Tondreau T Meuleman N Delforge A Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: proliferation, Oct4 expression, and plasticity Stem Cells 23 1105 1112 2005 15955825
  10. [10]Zuk PA Zhu M Mizuno H Multilineage cells from human adipose tissue: implications for cell-based therapies Tissue Eng 7 211 228 2001 11304456
  11. [11]Campagnoli C Roberts IA Kumar S Bennett PR Bellantuono I Fisk NM Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow Blood 98 2396 2402 2001 11588036
  12. [12]Keating A Mesenchymal stromal cells Curr Opin Hematol 13 419 425 2006 17053453 PMC3365862
  13. [13]Friedenstein AJ Chailakhjan RK Lalykina KS The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells Cell Tissue Kinet 3 393 403 1970 5523063
  14. [14]Friedenstein AJ Gorskaja JF Kulagina NN Fibroblast precursors in normal and irradiated mouse hematopoietic organs Exp Hematol 4 267 274 1976 976387
  15. [15]Grassel S Stockl S Jenei-Lanzl Z Isolation, culture, and osteogenic/chondrogenic differentiation of bone marrow-derived mesenchymal stem cells Methods Mol Biol 879 203 267 2012 22610563
  16. [16]Eslaminejad MB Mirzadeh H Mohamadi Y Nickmahzar A Bone differentiation of marrow-derived mesenchymal stem cells using beta-tricalcium phosphate-alginate-gelatin hybrid scaffolds J Tissue Eng Regen Med 1 417 424 2007 18247428
  17. [17]Reyes M Lund T Lenvik T Aguiar D Koodie L Verfaillie CM Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells Blood 98 2615 2625 2001 11675329
  18. [18]Tomic S Djokic J Vasilijic S Immunomodulatory properties of mesenchymal stem cells derived from dental pulp and dental follicle are susceptible to activation by toll-like receptor agonists Stem Cells Dev 20 695 708 2011 20731536
  19. [19]Toubai T Paczesny S Shono Y Mesenchymal stem cells for treatment and prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation Curr Stem Cell Res Ther 4 252 259 2009 19500066
  20. [20]Tse WT Pendleton JD Beyer WM Egalka MC Guinan EC Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation Transplantation 75 389 397 2003 12589164
  21. [21]Ramasamy R Tong CK Seow HF Vidyadaran S Dazzi F The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function Cell Immunol 251 131 136 2008 18502411
  22. [22]Che N Li X Zhou S Umbilical cord mesenchymal stem cells suppress B-cell proliferation and differentiation Cell Immunol 274 46 53 2012 22414555
  23. [23]Spaggiari GM Capobianco A Becchetti S Mingari MC Moretta L Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation Blood 107 1484 1490 2006 16239427
  24. [24]Deuse T Stubbendorff M Tang-Quan K Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells Cell Transplant 20 655 667 2011 21054940
  25. [25]Najar M Raicevic G Id Boufker H Modulated expression of adhesion molecules and galectin-1: role during mesenchymal stromal cell immunoregulatory functions Exp Hematol 38 922 932 2010 20570633
  26. [26]De Bruyn C Najar M Raicevic G A rapid, simple, and reproducible method for the isolation of mesenchymal stromal cells from Wharton’s jelly without enzymatic treatment Stem Cells Dev 20 547 557 2011 20923277
  27. [27]Battula VL Bareiss PM Treml S Human placenta and bone marrow derived MSC cultured in serum-free, b-FGF-containing medium express cell surface frizzled-9 and SSEA-4 and give rise to multilineage differentiation Differentiation 75 279 291 2007 17288545
  28. [29]Young RG Butler DL Weber W Caplan AI Gordon SL Fink DJ Use of mesenchymal stem cells in a collagen matrix for Achilles tendon repair J Orthop Res 16 406 413 1998 9747780
  29. [30]Wakitani S Saito T Caplan AI Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine Muscle Nerve 18 1417 1426 1995 7477065
  30. [31]Parker AM Katz AJ Adipose-derived stem cells for the regeneration of damaged tissues Expert Opin Biol Ther 6 567 578 2006 16706604
  31. [32]Kobayashi K Kubota T Aso T Study on myofibroblast differentiation in the stromal cells of Wharton’s jelly: expression and localization of alpha-smooth muscle actin Early Hum Dev 51 223 233 1998 9692792
  32. [33]Wulf GG Viereck V Hemmerlein B Mesengenic progenitor cells derived from human placenta Tissue Eng 10 1136 1147 2004 15363170
  33. [34]Chen MY Lie PC Li ZL Wei X Endothelial differentiation of Wharton’s jelly-derived mesenchymal stem cells in comparison with bone marrow-derived mesenchymal stem cells Exp Hematol 37 629 640 2009 19375653
  34. [35]Baksh D Yao R Tuan RS Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow Stem Cells 25 1384 1392 2007 17332507
  35. [36]Raynaud CM Maleki M Lis R Comprehensive characterization of mesenchymal stem cells from human placenta and fetal membrane and their response to osteoactivin stimulation Stem Cells Int 2012 658356 2012 22701494 PMC3373208
  36. [37]Zhu SF Zhong ZN Fu XF Comparison of cell proliferation, apoptosis, cellular morphology and ultrastructure between human umbilical cord and placenta-derived mesenchymal stem cells Neurosci Lett 541 77 82 2013 23523648
  37. [38]Stenderup K Justesen J Clausen C Kassem M Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells Bone 33 919 926 2003 14678851
  38. [39]Post S Abdallah BM Bentzon JF Kassem M Demonstration of the presence of independent pre-osteoblastic and pre-adipocytic cell populations in bone marrow-derived mesenchymal stem cells Bone 43 32 39 2008 18456590
  39. [40]Larsen KH Frederiksen CM Burns JS Abdallah BM Kassem M Identifying a molecular phenotype for bone marrow stromal cells with in vivo bone-forming capacity J Bone Miner Res 25 796 808 2010 19821776
  40. [41]De Ugarte DA Morizono K Elbarbary A Comparison of multi-lineage cells from human adipose tissue and bone marrow Cells Tissues Organs 174 101 109 2003 12835573
  41. [42]Lorenz K Sicker M Schmelzer E Multilineage differentiation potential of human dermal skin-derived fibroblasts Exp Dermatol 17 925 932 2008 18557932
  42. [43]Kern S Eichler H Stoeve J Kluter H Bieback K Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue Stem Cells 24 1294 1301 2006 16410387
  43. [44]Zhang X Hirai M Cantero S Isolation and characterization of mesenchymal stem cells from human umbilical cord blood: reevaluation of critical factors for successful isolation and high ability to proliferate and differentiate to chondrocytes as compared to mesenchymal stem cells from bone marrow and adipose tissue J Cell Biochem 112 1206 1218 2011 21312238
  44. [45]Dazzi F Krampera M Mesenchymal stem cells and autoimmune diseases Best Pract Res Clin Haematol 24 49 57 2011 21396592
  45. [46]Kebriaei P Robinson S Treatment of graft-versus-host-disease with mesenchymal stromal cells Cytotherapy 13 262 268 2011 21231805
  46. [47]Kode JA Mukherjee S Joglekar MV Hardikar AA Mesenchymal stem cells: immunobiology and role in immunomodulation and tissue regeneration Cytotherapy 11 377 391 2009 19568970
  47. [48]Krampera M Glennie S Dyson J Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide Blood 101 3722 3729 2003 12506037
  48. [49]Polchert D Sobinsky J Douglas G IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease Eur J Immunol 38 1745 1755 2008 18493986 PMC3021120
  49. [50]Rubinstein P Rosenfield RE Adamson JW Stevens CE Stored placental blood for unrelated bone marrow reconstitution Blood 81 1679 1690 1993 8096404
  50. [51]Augello A Tasso R Negrini SM Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway Eur J Immunol 35 1482 1490 2005 15827960
  51. [52]Yang SH Park MJ Yoon IH Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10 Exp Mol Med 41 315 324 2009 19307751 PMC2701980

Cited by

Sorted by citations

Authors
LI, X., BAI, J., JI, X., LI, R., XUAN, Y., & WANG, Y.
Affiliations
Jilin University (CN)
Corresponding author
WANG, YIMIN
ORCID
Venue
International Journal of Molecular Medicine
Publisher
Spandidos Publications
Published
2014-06-25
Volume
34
Issue
3
Pages
695-704
ISSN
  • 1107-3756 (ISSN-L)
  • 1791-244X
DOI
10.3892/ijmm.2014.1821
PMC
PMC4121354
OpenAlex
W2148064846
Cited by
301
References
1
Citations by year
2026: 10 · 2025: 21 · 2024: 25 · 2023: 24 · 2022: 29 · 2021: 39 · 2020: 33 · 2019: 40 · 2018: 19 · 2017: 19 · 2016: 22 · 2015: 18 · 2014: 1
FWCI
10.04
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • International Journal of Molecular Medicine (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
Keywords
mesenchymal stem cells, Wharton's jelly, bone marrow, adipose tissue, placenta, immunosuppression, T cell proliferation, T cell co-culture, osteogenic differentiation, adipogenesis, immune gene expression, TLR4, Notch gene, MHC class II, cell therapy
MeSH terms
Adipose Tissue, Adolescent, Adult, Bone Marrow Cells, Cell Count, Cell Differentiation, Female, Flow Cytometry, Gene Expression Regulation, Humans, Middle Aged, Osteogenesis, Placenta, Pregnancy, T-Lymphocytes, Biomarkers, Adipocytes, Coculture Techniques, Cell Proliferation, Adipogenesis, Young Adult, Mesenchymal Stem Cells, Wharton Jelly

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review